Expert: Small molecule oral GLP-1 receptor agonist with enhanced oral bioavailability for metabolic disease.

Everyday: A pill that mimics a gut hormone to reduce appetite and help with weight loss and blood sugar.

Targets: ["GLP-1"]

Primary EP: [{"id":"vista-pe1","name":"Change in body weight from baseline at Week 26","type":"PRIMARY","unit":"%","results":[{"arm":"Summary","value":"Met primary endpoint (specific % not yet disclosed)","p_valu

Primary EP: [{"id":"sol-pe1","name":"Change in HbA1c from baseline at Week 26","type":"PRIMARY","unit":"%","results":[{"arm":"Summary","value":"Met primary endpoint vs placebo (specific reduction not yet disclose

Elecoglipron - Obesity/T2DM - Ph2b - Full Data (ADA 2026) ADA June 2026

Oral, once-daily, small-molecule GLP-1 receptor agonist (non-peptide). Licensed from Eccogene (Nov 2023, USD185M upfront, up to USD1.825B milestones). Key differentiator: NO food restrictions (can take fed or fasted) unlike oral semaglutide (Rybelsus) which requires 30min fasting. Once-daily pill vs weekly injections. Phase 2b VISTA (obesity, n=310): Met primary endpoint for weight loss at 26 weeks. Full data at ADA June 2026. Phase 2b SOLSTICE (T2DM, n=406): Met primary endpoint for HbA1c reduction vs placebo; included semaglutide active comparator arm. Full data at ADA June 2026. AZN advancing to Phase 3 in 2026 (confirmed Q4:25 earnings Feb 10, 2026). Phase 3 program includes monotherapy, combination, and CVOT trials. Competitive context: LLY orforglipron is ahead (Phase 3 complete, FILED). LLY Phase 2 showed 14.7% weight loss at 36wk highest dose. Elecoglipron data not yet disclosed. ADA June 2026 is the key catalyst. Also: AZN acquired rights to SYH2082 (long-acting GLP-1R/GIPR dual agonist) from CSPC for USD1.2B upfront (Jan 30, 2026) complements elecoglipron with next-gen injectable combo.